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Abstract
Background: Hepatic encephalopathy (HE) is a frequent and severe complication of cirrhosis. A single
determination of ammonia in venous blood correlates poorly with neurological symptoms. Thus, a better biological
marker is needed.
Aim: To make a diagnosis of HE, we explored the value of ammonia in capillary blood, an equivalent to arterial
blood, measured at bedside following an oral glutamine challenge.
Methods: We included 57 patients (age 56 yrs; M/F: 37/20) with cirrhosis (alcoholic = 42; MELD score 13.8 [7-29],
esophageal varices = 38) and previous episodes of HE (n = 19), but without neurological deficits at time of
examination, and 13 healthy controls (age 54 yrs). After psychometric tests and capillary (ear lobe) blood ammonia
measurements, 20 gr of glutamine was administered orally. Tests were repeated at 60 minutes (+ blood ammonia
at 30’). Minimal HE was diagnosed if values were > 1.5 SD in at least 2 psychometric tests. Follow-up lasted
12 months.
Results: The test was well tolerated (nausea = 1; dizziness = 1). Patients showed higher values of capillary blood
ammonia over time as compared to controls (0’-30’-60 minutes: 75, 117, 169 versus 52, 59, 78 umol/L, p < 0.05). At
baseline, 25 patients (44%) had minimal HE, while 38 patients (67%) met the criteria for HE at 60 minutes (chi
2:p<
0.01). For the diagnosis of minimal HE, using the ROC curve analysis, baseline capillary blood ammonia showed an
AUC of 0.541 (CI: 0.38-0.7, p = 0.6), while at 60 minutes the AUC was 0.727 (CI: 0.58-0.87, p < 0.006). During follow-
up, 18 patients (31%) developed clinical episodes of HE. At multivariate analysis, the MELD score (1.12 [1.018-1.236]),
previous episodes of HE (3.2[1.069-9.58]), but not capillary blood ammonia, were independent predictors of event.
Conclusions: In patients with cirrhosis and normal neurological examination, bedside determination of ammonia
in capillary blood following oral glutamine load is well tolerated and achieves a better diagnostic performance for
minimal HE than basal capillary ammonia levels. However, capillary blood ammonia is a poor predictor of
development of clinically overt HE.
Background
Hepatic encephalopathy (HE) is a common complication
of cirrhosis that affects quality of life, increases the risk of
accidents, and is an independent predictor of poor out-
come [1,2]. When neurological deficits are subtle but the
neurological clinical examination is normal, a condition
referred to as minimal HE [3], patients are exposed to a
risk of developing clinical episodes of HE over time [4].
The presence of HE in cirrhosis is a prognostic marker of
severity and a valid indication for liver transplantation,
although it is not considered in the model for end-stage
liver disease (MELD) score on which organ distribution is
based in most liver transplant centres [5].
Neurological alterations observed in HE are postulated
to result from the exposure of the brain to abnormally
elevated concentrations of ammonia present in the
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portosystemic collaterals [6]. Accordingly, high ammonia
levels have been associated with large portosystemic col-
laterals such as esophageal varices in patients with cir-
rhosis [7]. However, ammonia determination is not
currently accepted as a reliable marker to identify
patients with HE [8]. Hyperammonemia arises from the
production by colonic bacteria and the small intestine
through an increased intestinal glutaminase activity [9].
Although the pathogenesis of HE is still incompletely
elucidated, the ammonia hypothesis remain central [10]
and a large number of experimental data support the
role of hyperammonemia in the direct and indirect
alterations of brain function that characterize HE [11].
Making a diagnosis of HE may be straightforward when
a patient with cirrhosis presents with obvious neurologi-
cal deficits such as altered consciousness, but it is much
more challenging in the presence of more subtle neurop-
sychological or personality changes that are not uncom-
mon in an outpatient population of cirrhotics (up to 62%
in a recent report [12]). In fact, it is recommended to
search for minimal HE in patients who complain of cog-
nitive alterations, a disturbed sleep [13], or are exposed
to an accident risk while driving or at their work-place.
As neurological deficits associated with minimal HE are
clinically subtle, this complication may be underdiag-
nosed and may negatively impact patients’ management.
Accordingly, minimal HE can be accessible to medical
therapy that may improve quality of life and prevent the
development of clinical episodes of overt HE.
In clinical practice, the available tools for the diagnosis
of HE include clinical scales to assess the mental status,
such as the West-Haven scale [14], and a number of psy-
chometric tests to assess the presence of congnitive defi-
cits [15]. Neuroradiological imaging is mostly directed at
excluding other neurological disorders. Blood ammonia
concentration in the context of HE is difficult to interpret,
as the correlation between neurological symptoms and
ammonia blood levels is variable, with a wide overlap
across different stages of HE [8]. Some [16,17], but not all
[7,18] studies report a closer correlation with arterial as
compared to venous ammonia blood levels. The diagnosis
of minimal HE is therefore challenging for the clinician
who has to choose between a suboptimal biological test or
a number of neuropsychological tests that may be time
consuming, need to be adjusted for several parameters,
and are subject to learning biases [3].
To improve the performance of blood ammonia for
the diagnosis of minimal HE, we hypothesized that mea-
suring ammonia in arterialized blood following oral glu-
tamine-induced hyperammonemia and consecutive
cognitive deterioration would increase the diagnostic
yield of this biological test. Therefore, we explored the
value of capillary blood ammonia measured at bedside
following an oral glutamine challenge to unmask HE in
patients with cirrhosis.
Methods
Patients
Between January 2008 and February 2009, a total of 60
patients with cirrhosis were considered eligible for this
study. Thirty eight were outpatient, and 22 patients were
hospitalized for investigation of a chronic liver disease or
as part of an assessment for liver transplantation. The
d i a g n o s i so fc i r r h o s i sw a sb a s e do nh i s t o l o g yi n5 4
patients, and based on clinical, biological and radiological
alterations in the other 6 patients. Inclusion criteria were
as follows: cirrhosis in a stable condition with mild to
severe liver failure (MELD 10 to 30), age 18 to 70 yrs,
with a grade 0 of HE according to West-Haven criteria
[14], and a written informed consent to participate.
Exclusion criteria were the following: clinically overt HE
(grade I or higher), diagnosis of a neurological or psy-
chiatric disease other than HE, current use of psychotro-
pic medications including benzodiazepines, recent (< 3
months) modification in the routine treatment of HE
including nonabsorbable disaccharides and antibiotics,
active alcoholism, active or recent use of nonsteroidal
antiinflammatory drugs that may affect intestinal muco-
sal barrier, diagnosis of severe gastroparesis, history of
small bowel surgical resection, inability to perform psy-
chometric tests, and absence of informed consent.
Three patients with grade 1 HE according to West-
Haven criteria [14] on the day of the test were excluded.
Table 1 provides the characteristics of the 57 enrolled
patients. The majority were male with alcoholic cirrhosis
with clinically significant portal hypertension invasively
measured in 51 patients. Most patients had moderate to
severe liver failure, and large portosystemic collateral
veins were visible at imaging studies in 39 out of the 57
patients. Four patients had a transjugular intrahepatic
Table 1 Patients characteristics
Age (yrs) 56.4 [42-69]
Gender (M/F) 37/20
Etiology of cirrhosis: Alcoholic 42
Other 15
MELD score 13.8 [7-29]
Child class (A/B/C) 10/33/14
HVPG (mmHg) 16 [13-22]
Esophageal varices 38/57
Ascites 29/57
TIPS 4/57
Previous episodes of HE 19/57
Nonabsorbable disaccharides 20/57
Antibiotics 17/57
Abbreviations: MELD: model for end-stage liver disease; HVPG: hepatic venous
pressure gradient. TIPS: transjugular intrahepatic portosystemic shunt.
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recurrent bleeding (n = 2). Chronic administration of
nonabsorbable disaccharides or antibiotics were reported
in 20 and 17 patients, respectively.
Design of the study
Included patients were invited to undergo a baseline
capillarized blood ammonia measurement prior to the
p e r f o r m a n c eo fp s y c h o m e t r i ct e s t s ,f o l l o w e db ya no r a l
glutamine load. Blood ammonia levels were again deter-
mined at 30 and 60 minutes, together with psychometric
tests. Basing ourselves on peak ammonia levels in a pre-
vious study [19], we decided not to extend the observa-
tion period beyond 60 minutes. The study design is
summarized in Figure 1.
Psychometric tests
The diagnosis of minimal HE was based on psychometric
tests that evaluate attention, executive function, speed of
information processing and motor functions, as recom-
mended in previously published guidelines [3]. To mini-
mize the complexity of a comprehensive but demanding
neuropsychiatric evaluation, we constructed a short bat-
tery of tests that included the Trail Making Test part A
and B, as well as the Purdue Pegboard. Trail tests detect
impairment in psychomotor speed and mental flexibility,
both domains that are often impaired in HE [3]. Results
are expressed in seconds. The Purdue Pegboard (Lafay-
ette Instrument, IN, USA) is a validated method for eval-
uating the velocity and accuracy of fine movements of
both upper extremities by measuring how quickly a sub-
ject can properly insert pins into grooved holes during a
30-second period [20]. Results are expressed in units
(number of pins inserted during a given time period).
The short psychometric tests battery was administered
by trained hepatologists familiar with neuropsychological
evaluation (SD, LS), under the supervision of a senior
neurologist (PRB). The tests were performed while com-
fortably seated in a quiet and well-lit room, after a thor-
ough explanation of the test and a practice run have been
given to all patients. A modified version of the Trail
Making Test A and B was used for the repeated evalua-
tion at 60 minutes to avoid learning biases. All results
were adjusted for age, gender and level of education
using normative data. The presence of minimal HE was
defined by the presence of at least 2 abnormal psycho-
metric tests values (> 1.5 standard deviation), including
the Trailmaking test B, in the absence of overt neurologi-
cal manifestations, as reported [21]. Healthy subjects
were also asked to perform Trail Making Test A and B at
baseline and at 60 minutes.
Oral glutamine challenge
In a fasting and metabolically stable state, patients were
asked to ingest a solution of 20 gr of glutamine (Gluta-
min OX5, Fresenius-Kabi, Stans, Switzerland) dissolved
in 50 ml tap water. Patients under chronic disaccharides
or antibiotics remained so until the test. We chose this
glutamine dosage as it induces a significant rise in blood
ammonia following oral intake [22]. Ammonia was mea-
sured at bedside using a point-of-care testing (POCT)
device (PocketChem Ammonia Checker II, Arkray Inc.,
Kyoto, Japan), a convenient and accurate method in both
arterial and capillary blood samples [23,24], that delivers
results in a few minutes without requiring centrifugation
nor transportation on ice. We collected capillary blood
f r o mt h ee a r - l o b ea n dp l a c e di ti m m e d i a t e l yo nt h e
reagent strip for analysis. We chose not to define an a
priori pathological threshold for the rise in blood ammo-
nia as there is no data on capillary blood value after such
an amino acid challenge.
In a subset of 8 hospitalized patients, ammonia was
determined simultaneously in capillary blood from the
ear-lobe and in venous blood from a cannula inserted
into the antecubital vein.
Any symptoms that appeared during or after the 60
minutes period was carefully recorded. In order to deter-
mine a physiological response to the oral glutamine load
in terms of capillary blood ammonia, 13 healthy subjects
(male/female: 5/8; age 54 yrs [29-72]) also underwent the
test.
Clinical outcome
All patients were followed-up for one year after the test,
and all clinical episodes of HE were identified and fully
characterized using patients’ hospital records as well as
information obtained from the family or general
practitioner.
Statistical analysis
Statistical tests were performed using Statistical Package
for the Social Sciences SPSS version 10.0 (SPSS Inc. Chi-
cago, IL, USA) Continuous variables were expressed as
mean and standard deviation or median value (interquar-
tile range [IQR]) as appropriate. The results of psycho-
metric tests were transformed into Z-scores, which
allows to normalize the value to a standard distribution
Figure 1 Design of the study.
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squared test as appropriate. To test for blood ammonia
changes over time, we used the one way repeated mea-
sures ANOVA test with Dunnett’s test. We constructed
receiver-operating characteristics (ROC) curves to assess
for overall accuracy of capillary blood ammonia levels
and to identify optimal cutoffs. To identify independent
predictors of development of HE episodes during follow-
up, we performed a multivariate logistic regression analy-
sis using a Cox proportional hazard model. A 2-sided p
value of less than 0.05 was considered statistically
significant.
Ethical considerations
The study protocol was approved by the Ethics Com-
m i t t e eo ft h eG e n e v aU n i v e r s i t yH o s p i t a l sa n db yt h e
Swiss Agency for Therapeutic Products (SwissMedic)
authorities. The study was conducted in accordance
with the ethical principles of the Declaration of Helsinki.
All patients and controls gave written, informed consent
to participate.
Results
Prevalence of minimal HE
All patients completed the short neuropsychological tests
successfully. At baseline, 25 patients (44%) met the criteria
for minimal HE, while this proportion rose to 67% (38 out
of 57 patients) at the evaluation performed 60 minutes
post glutamine challenge (chi
2 : p < 0.01). Changes in psy-
chometric tests results are given in table 2.
Oral glutamine load and blood ammonia
The oral glutamine challenge was completed in all patients
and the healthy subjects. Tolerance to the test was overall
excellent, although one patient presented transient nausea
after 30 minutes, and one healthy subjects reported mild
dizziness at 45 minutes after glutamine ingestion. There
was no modification in patients’ neurological status during
or after the test.
We observed a progressive and significant increase in
capillary blood ammonia in patients with cirrhosis, while
values remained statistically unchanged in healthy
subjects (see table 3 and Figure 2). In the subgroup of 8
patients who had ammonia levels determined simulta-
neously in two vascular beds, we observed a tendency
towards higher values in capillary as compared to
venous blood (see Figure 3), but without reaching the
level of significance. The rise in capillary blood ammo-
nia was not influenced by the degree of liver dysfunction
using a cut-off of 12 in the MELD score (see Figure 3).
Capillary blood ammonia and hepatic encephalopathy
At baseline, patients with cirrhosis, with and without
minimal HE demonstrated similar capillary blood
ammonia values. 60 minutes following glutamine load,
there was a trend of higher values in patients with HE
as compared to those without HE, but the difference
was not significant (183 [45-290] versus 144 [49-264]
umol/l, respectively, p = 0.133) (see Figure 4). To
further explore the diagnostic accuracy of capillary
blood ammonia for minimal HE, ROC curves were con-
structed and the area under the ROC curve (AUROC)
was computed. The AUROC for making the diagnosis
of minimal HE at baseline was 0.541 (95% confidence
interval (CI), 0.38-0.7, p = 0.6), while at 60 minutes after
the test it was 0.727 (95% CI, 0.58-0.87, p < 0.006) (see
Figure 5).
The subgroup of 18 patients with previous episodes of
HE had higher 60 minutes post glutamine ammonia
levels compared to those who never experienced clinical
episodes of HE (181 ± 13 vs 163 ± 11 umol/l, p < 0.05).
No clinically overt HE developed in the 4 patients
with TIPS after the oral glutamine test. Table 4 provides
the individual values of capillary blood ammonia during
the test period, as well as the MHE status.
Incidence of hepatic encephalopathy during the
follow-up
During follow-up, 18 patients, 9 of whom had a past
history of overt HE, presented clinical episodes of HE at
a median time of 59 days ([50-320]) after the oral gluta-
mine test, 2 patients died of end-stage liver failure, and
3 patients underwent liver transplantation. Precipitating
factors of progression to overt HE included excess of
diuretics, gastrointestinal bleeding, use of psychoactive
drugs and infections in 10 patients, while no precipitant
could be identified in the remaining 8 patients.
The following variables were entered into a predictive
statistical model for HE: age, MELD score, 60’ post gluta-
mine capillary blood ammonia, previous episodes of HE,
the hepatic venous pressure gradient, and presence of
esophageal varices. In the Cox multivariate regression
analysis, only the MELD score (HR 1.122; 95% CI, 1.018-
1.236) and previous episodes of HE (HR 3.2; 95% CI,
1.069-9.58), but not capillary blood ammonia, were inde-
pendent predictor of development of overt HE during
Table 2 Changes in psychometric tests after glutamine
load in patients and in healthy subjects
Test patients Baseline 60 minutes P value
Trail test A 2.7 ± 2.3 3.4 ± 2.5 0.04
Trail test B 2.4 ± 2.1 3.5 ± 29 0.001
Pegboard 0.09 ± 1.4 0.01 ± 1.5 0.63
Test controls
Trail test A 0.42 ± 1.2 0.51 ± 1.3 0.81
Trail test B 0.80 ± 1.5 0.77 ± 0.9 0.9
Note: values expressed as Z-scores.
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in the model did not modify the results of the analysis.
Discussion
Making a diagnosis of minimal HE is challenging for the
clinician, who needs a sensitive, reliable, and easy-to-use
diagnostic tool. However, at present, neuropsychological
evaluation and electrophysiological tests do not fulfill
these requirements. This aspect may explain in part why
only a minority of hepatologists are screening for mini-
mal HE in daily practice [25]. Therefore, a simple test
would be welcome and greatly facilitate the diagnosis and
thus the management of HE. In our study, we tried to
improve the diagnostic accuracy of blood ammonia, a key
substance in the pathogenesis of HE, for the presence of
minimal HE. To do so, we used capillary blood as an
equivalent to the arterial compartment, and induced
hyperammonemia via small intestine ammonia produc-
tion to unmask HE. Finally, we designed the test as a
bedside procedure fulfilling the definition of POCT to
improve patients’ and clinician’s acceptance.
F i r s to fa l l ,u s i n go u rs h o r tt e s tb a t t e r y ,w ec o n f i r m e d
the high prevalence of minimal HE (44%) in our patients
with advanced cirrhosis (82% of Child B and C), consis-
tent with published data [3,4]. Secondly, we
demonstrated that an amino acid load using oral gluta-
m i n ea tah i g h e rd o s et h a nu s e di np r e v i o u ss t u d i e s
[26,19] is well tolerated in patients with moderate to
severe liver insufficiency. We also observed that the pre-
sent test didn’t precipitate any clinical episodes of HE in
the 4 patients with TIPS, as this situation worsens portal-
systemic shunting and makes the patient more vulnerable
to the HE [27]. Our results also demonstrate that capil-
lary blood ammonia is not an accurate biological marker
of minimal HE in patients with cirrhosis, nor a reliable
predictor of future episodes of overt HE during follow-
up. Nevertheless, we show that the diagnostic value of
capillary blood ammonia can be substantially improved
following an oral aminoacid load, raising the AUROC
value from 0.541 at baseline to 0.727 at 60 minutes after
the oral glutamine challenge. This significant and rapid
elevation in blood ammonia after the test is consistent
with the significant contribution of the small intestine to
the production of ammonia [28], in addition to the well-
accepted role of colonic bacteria. The presence and
severity of portosystemic venous collaterals is another
important parameter that determines blood ammonia
levels [7]. Ortiz et al. [29] reported a similar increase in
capillary blood ammonia following an oral glutamine
challenge in patients with congenital portosystemic
shunts as compared to patients with cirrhosis. In our
study, most patients had evidence of portosystemic col-
lateralization visible on different imaging modalities pre-
venting an accurate analysis, therefore we did not include
this parameter nor the value of portal pressure in the sta-
tistical model.
Induced hyperammonemia using either glutamine
alone [22] or combined with other amino acids [30] is
associated with electroencephalographic, brain magnetic
resonance and biochemical alterations, the neuropsycho-
logical consequences of which are inconstant, showing
either absent [31], partial [22] or generalized [32] dete-
rioration of tests’ performance. In the present study, we
observed changes limited to the Trail A and B tests,
both commonly used components of standard test bat-
tery for the detection of minimal HE [3], suggesting that
visuo-spatial skills and visuo-motor coordination are
affected by hyperammonemia. We also explored whether
induced hyperammonemia could predict the develop-
ment of overt HE during follow-up, and found that post
test capillary blood ammonia was a poor predictor of
Figure 2 Changes in capillary blood ammonia during the
glutamine challenge in patients with cirrhosis (n = 57) and in
healthy subjects (n = 13). # p < 0.05 versus values in healthy
subjects; * p < 0.05 versus baseline values.
Table 3 Evolution of capillary blood ammonia after the oral glutamine challenge in patients and in healthy subjects
Patients Baseline 30 minutes 60 minutes
75.2 ± 22 umol/l 117 ± 16 umol/l*# 169 ± 51 umol/l*#
Healthy subjects Baseline 30 minutes 60 minutes
52 ± 11 umol/l 59 ± 15 umol/l 76 ± 23 umol/l
Note: * p < 0.05 versus baseline value; # p < 0.05 versus value in healthy subjects.
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s t u d yb yR o m e r o - G o m e ze ta l .[ 1 9 ]w h or e p o r t e dt h a t
an abnormal ammonia response after oral glutamine
was predictive of the development of overt HE during
follow-up. The distribution of liver disease severity in
the 2 studies (Child A patients: 75% versus 17% in our
study) and the absence of any treatment for HE that
may influence the ammonia response following a gluta-
mine challenge [33,34], could explain these differences.
Our study is in line with previous results which
showed that determination of blood ammonia levels,
either a single venous dosage [18] or in capillary blood
after induced hyperammonemia, correlates only poorly
with symptoms of HE. Whether determination of
ammonia in a arterialized-venous blood, as in our study,
shows higher values as compared to venous blood has
been proposed [16] but not confirmed in our small sub-
group of 8 patients. Thus, additional parameters such as
size and extension of portosystemic shunts [29,15],
hyponatremia [35], nutritional status [36], the presence
of hepatitis C infection [37], together with the presence
of a systemic inflammatory reaction syndrome (SIRS)
[38] that may modulate ammonia neurotoxicity at the
cerebral level, are factors that influence the development
of HE. We were however not able to examine all these
parameters in our cohort, as values of serum creatinine,
sodium, and C-reactive protein were available only in a
limited number of patients.
Conclusions
In conclusion, we demonstrated that determination of
capillary blood ammonia after a bedside oral glutamine
challenge is feasible, well tolerated and superior to
basal levels for the diagnosis of minimal HE in patients
with cirrhosis and moderate to severe liver failure. The
increase in blood ammonia, absent in healthy subjects,
correlated imperfectly with the deterioration in psy-
chometric tests. Thus, in spite of a recognized impor-
tant pathogenic role in HE, blood ammonia, even in a
capillary, arterialized vascular bed, remains an approxi-
mate marker for the presence of HE. According to our
data in unselected patients with cirrhosis, ammonia
determination in capillary blood after an oral gluta-
mine challenge is not a valid tool for the diagnosis of
HE and a poor predictor of future clinical episodes of
HE.
Figure 4 Blood ammonia levels according to the presence
(MEH+) or absence (MEH-) of minimal HE at baseline and 60
minutes aftert the oral glutamine challenge in patients with
cirrhosis.
Figure 3 Panel A: Evolution of ammonia in samples obtained simultaneously in capillary and venous blood in a subgroup of 8
patients with cirrhosis. # p < 0.05 versus baseline. Panel B: Capillary blood ammonia changes over the test period in patients with cirrhosis
according to the MELD score using a cut-off of 12.
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